STAAR Surgical Company (STAA) Stock Price & How to Invest
Last updated November 2026
Short answer
STAA is an ordinary Nasdaq stock that any U.S. brokerage account can hold. It is a single-product eye surgery company: STAAR sells the EVO Implantable Collamer Lens, which corrects nearsightedness without removing corneal tissue, and China supplies close to half its sales. Shares closed near ~$24.12 on November 20, 2026 (~$1.21 billion market value), up about 2% year to date and down about 12% over one year, after holders rejected Alcon's $30.75 cash offer in January.
STAA stock price
As of 2026-11-20, STAAR Surgical Company (STAA) last closed at $24.22, down 13.5% over the past year. Over the past 52 weeks it has traded between $16.10 and $33.34.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or STAAR Surgical Company's investor relations page. Walnut is informational, not investment advice.
STAA key stats
At $24.22 on November 20, 2026, STAAR Surgical Company (STAA) has a market cap of $1.2B and a P/E of 2422.0 on trailing earnings (21.4 on forward earnings).
- Market cap
- $1.2B
- P/E (trailing)
- 2422.0
- P/E (forward)
- 21.4
- EPS (trailing 12 months)
- $0.01
- Price to book
- 3.2
- Beta
- 1.20
Market cap, P/E and yield are measured at the $24.22 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with STAAR Surgical Company (STAA)?
The last two weeks for STAAR Surgical Company, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- STAA closed at $24.22 on November 20, 2026, down 8.2% over the past five trading days (from $26.39).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does STAAR Surgical Company (STAA) do?
STAAR Surgical, based in Lake Forest, California, makes implantable lenses for vision correction. Its main product is the EVO Implantable Collamer Lens (ICL), a soft lens that a surgeon slips behind the iris and in front of the eye's natural lens, correcting myopia, with or without astigmatism, without removing corneal tissue the way LASIK or SMILE do. The lens can be taken out later. It is sold in more than 75 countries, gained U.S. FDA approval in its EVO form in 2022, and is manufactured in Monrovia, California and in Switzerland. Nearly all revenue comes from the ICL family, including the newer EVO+ with a larger optic and toric versions for astigmatism.
The last two years have been unusually eventful. Net sales fell 23.7% in 2025 to ~$239.4 million, with a ~$80.4 million net loss, as Chinese distributors worked through excess inventory. Alcon agreed in August 2025 to buy the company for $28 a share, raised the price to $30.75 in December after a go-shop period, and still lost the vote: on January 6, 2026, about 27.3 million shares voted against and 14.9 million for. The agreement was terminated with no fee owed by either side. A cooperation agreement with Broadwood Partners, the largest holder, followed on January 14, bringing three new directors and the exit of CEO Stephen Farrell. Warren Foust, previously president and chief operating officer, became permanent CEO on August 4, 2026.
The business has since recovered. Sales for the first nine months of 2026 reached a record ~$270.5 million with ~$18.8 million of net income. The third quarter showed ~$83.4 million of sales, down 12% only because the prior year included ~$25.9 million of deferred China shipments, and gross margin dropped to 70.9% on tariffs. Cash and investments stand at ~$206.4 million with no debt, and the board approved a $50 million buyback in September. Third-quarter adjusted EPS of $0.19 came in a cent under the $0.20 consensus in Yahoo Finance data. At ~$24.12 on November 20, 2026 the stock trades about 22% below the rejected $30.75 offer, so holders are now carrying China, tariff and competition risk directly. The nine analysts in Yahoo Finance's current count rate it a Buy on average, with a mean target of about $28.56.
What's driving STAAR Surgical Company (STAA)?
1. China demand and pricing
China produced ~$52.3 million of sales in the second quarter of 2026 and ~$39.3 million in the third, against ~$44.1 million from every other market combined in the third quarter. Management says distributor unit shipments rose 12.4% over the first nine months and that its share of the Chinese refractive surgery market grew as patients chose the ICL over laser procedures. Average selling prices rose as EVO+ and toric lenses took a bigger part of the mix, and third-quarter growth in China came entirely from price because the company could not make enough lenses to meet demand. Distributor inventory ended the quarter below the six-month target, so supply, not demand, limited the quarter.
2. Growth outside China
Sales outside China rose 13% in the third quarter to ~$44.1 million. EMEA grew 31% (51% excluding the Middle East) and the Americas grew 14%, while Asia-Pacific excluding China rose only 4% with declines in Japan and South Korea. The U.S. is still small, at ~$6.5 million in the third quarter, four years after the EVO lens won FDA approval, so U.S. surgeon adoption is still at an early stage. The 2025 numbers set the floor: sales excluding China grew 6.6% that year to ~$161.7 million. A steadier non-China base would make the company less exposed to one distributor network and one regulator.
3. Margin repair after the tariff hit
Gross margin slipped to 70.9% in the third quarter of 2026 from 82.2% a year earlier (75.5% excluding the deferred China revenue), largely because U.S.-made lenses shipped to China carried tariffs. By the end of the quarter all China-bound manufacturing had moved to Switzerland, and management expects fourth-quarter margins above the third, with unit costs improving further in 2027. Operating expenses fell to ~$174.2 million over nine months from ~$207.6 million, and the company says it is on track for a $225 million annual target. Adjusted EBITDA was ~$58.8 million over the same nine months, against breakeven in the fourth quarter of 2025.
4. Capital return and governance under new leadership
STAAR has ~$206.4 million in cash and investments, no debt, and a $50 million share repurchase program authorized in September 2026, which management tied to its view that the shares are undervalued. Since the Broadwood cooperation agreement the board has seven seats, three of them filled by people linked to Broadwood and Yunqi Capital, the two holders that led opposition to the Alcon deal. Foust has set three company goals: revenue growth, profit expansion and faster product development. Ying Chen was elevated to president of STAAR Surgical China. How the new board allocates the cash pile, between buybacks, manufacturing capacity and research, will shape per-share results over the next few years.
What are the risks to STAAR Surgical Company (STAA)?
Close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. Chinese competition is now real. Eyebright Medical's Loong Crystal PR phakic lens was approved by China's NMPA in January 2025, and a small Fudan University study found similar efficacy and safety against the EVO ICL in paired eyes. Hospital procurement policy in China, including volume-based purchasing that has squeezed prices for cataract lenses, could reach phakic lenses. Tariffs already cut third-quarter gross margin by several points, and U.S.-origin product sold into China is still subject to them. Japan and South Korea are declining. The ICL is effectively the whole company, so a safety signal, a recall or a manufacturing problem at either plant would hit every line of the income statement. Finally, the share price no longer has a takeover floor. Holders who rejected $30.75 are relying on the standalone plan, and the stock has traded between ~$15.59 and ~$35.87 over the past 52 weeks.
What is the STAAR Surgical Company (STAA) forecast?
9 analysts publish price targets on STAA, averaging $28.56 as of November 2026, or +17.9% against the $24.22 share price on November 20, 2026. The published targets run from $19.00 to $37.00, a moderate spread, and the ratings split 4 buy, 6 hold, 1 sell. Over the last six months there has been 1 raise and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full STAA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is STAA a buy or a sell?
We give no verdict on STAAR Surgical Company. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. China demand and pricing. China produced ~$52.3 million of sales in the second quarter of 2026 and ~$39.3 million in the third, against ~$44.1 million from every other market combined in the third quarter. The most optimistic published target, $37.00, assumes this works close to its best case.
The case against. Close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. The most pessimistic target, $19.00, is roughly what STAA is worth if this bites instead.
Read the full bull and bear case on STAA, including what would have to change to break either one. Walnut is not an investment adviser.
How is STAAR Surgical Company (STAA) valued?
Market cap, P/E and dividend yield at today's price are in the STAA key stats above. The business figures below come from STAAR Surgical Company's reported results as of November 2026 and change when it next reports.
- Revenue (TTM through Q3 2026): ~$328M
- Net income (TTM through Q3 2026): ~breakeven (~$18.8M for 9M 2026)
- Adjusted EBITDA (9M 2026): ~$58.8M
- Gross margin (Q3 2026): ~70.9% (82.2% a year earlier)
- Cash and investments (Oct 2, 2026): ~$206.4M, no debt
As of November 2026: Trailing revenue of about $328 million combines the weak fourth quarter of 2025 (~$57.8 million and an ~$18.3 million loss) with three strong 2026 quarters, so the trailing GAAP profit of roughly zero understates the current run rate. Taking off the cash, enterprise value is about $1.0 billion, around 3.1 times trailing sales and about 13 times nine-month adjusted EBITDA annualized; the forward P/E is about 21 on 2027 EPS estimates near $1.13. The shares sit about 22% below Alcon's rejected $30.75 offer and under the ~$28.56 mean analyst target, with a Buy average from nine analysts.
Who competes with STAAR Surgical Company (STAA)?
Laser vision correction (LASIK, PRK, SMILE)
The ICL's main rival is the laser. Carl Zeiss Meditec's SMILE platform is widely used in China, and Alcon, Johnson & Johnson Vision and Bausch + Lomb sell excimer and femtosecond laser systems. Laser surgery is usually cheaper per eye, so the ICL competes on high myopia, thin corneas and reversibility.
Other phakic lens makers
Eyebright Medical's Loong Crystal PR entered the Chinese market in February 2025 and is the first domestic posterior chamber phakic lens to compete head-on with the ICL. Iris-fixated lenses such as Ophtec's Artisan/Artiflex are an older alternative in some markets. More Chinese entrants would pressure price and share.
Large ophthalmic device groups
Alcon, Johnson & Johnson Vision, Bausch + Lomb and Carl Zeiss Meditec dominate cataract lenses and surgical equipment, with sales forces many times STAAR's size. Alcon's 2025 bid showed the strategic interest. Any of them could license or develop a competing implantable lens, or bundle refractive offerings with equipment surgeons already own.
What stocks are similar to STAAR Surgical Company (STAA)?
Other names that sit close to STAA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in STAAR Surgical Company (STAA)
There are three common ways to get STAA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so STAA sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where STAA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on STAAR Surgical Company (STAA)
STAAR is a standalone, debt-free, profitable again lens maker whose results swing on Chinese demand and tariffs, priced at about 3.7 times sales after its holders turned down a $30.75 takeover.
More on STAAR Surgical Company (STAA)
Whether STAA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is STAA a buy or a sell?, and where the stock could go from here in the STAA stock forecast.
For income investors, whether STAA pays a dividend and how the payout looks is covered in does STAA pay a dividend? And to weigh STAA against a peer, read the full side-by-side comparisons: STAA vs PRK and STAA vs ICL.
Wondering how STAA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about STAAR Surgical Company
Ask Walnut's AI anything about STAA and see how it fits what you own.
FAQ
How do you invest in STAAR Surgical stock?
+
STAAR Surgical trades on the Nasdaq under the ticker STAA, so any brokerage account that offers U.S. stocks can hold it, including apps that sell fractional shares. Shares closed near ~$24.12 on November 20, 2026, a market value of about ~$1.21 billion across roughly 50.5 million shares. The company pays no dividend; it returns cash through a $50 million buyback authorized in September 2026. Because one product line and one country (China) drive most of the results, many investors size STAA as a smaller satellite holding inside a broader healthcare or medical device allocation. Medical device ETFs that hold small caps may include it at low weights, but the stock itself is the only way to get concentrated exposure to the ICL. Walnut can show how a position like this sits beside the rest of a portfolio; it is not an investment adviser and does not make buy or sell calls.
What happened to the Alcon acquisition of STAAR Surgical?
+
It failed. Alcon agreed on August 4, 2025 to buy STAAR for $28 a share in cash. Broadwood Partners, the largest holder, and Yunqi Capital campaigned against the price. After a go-shop period produced no rival bid, Alcon raised the offer to $30.75 in December 2025, about $1.6 billion of equity value. At the special meeting on January 6, 2026, roughly 27.3 million shares voted against and 14.9 million for, so the merger was not approved. STAAR's 8-K filed that day (Items 1.02 and 5.07) confirms the agreement was terminated effective January 6, with no termination fee owed by either company. STAAR has traded as a standalone public company since, and a January 14 cooperation agreement gave Broadwood-linked nominees board seats.
What is the EVO ICL and how does it differ from LASIK?
+
The EVO Implantable Collamer Lens is a thin, flexible lens made of Collamer, a collagen copolymer, that a surgeon places behind the iris and in front of the eye's natural lens through a small incision. It corrects nearsightedness and, in toric versions, astigmatism. LASIK, PRK and SMILE reshape the cornea by removing tissue with a laser, which cannot be undone. The ICL leaves the cornea intact and can be removed or exchanged, which makes it suited to patients with high myopia or thin corneas who are poor laser candidates. The EVO design includes a central port that removed the need for a separate laser hole in the iris used with earlier models. Per eye it usually costs more than laser surgery, so its growth depends on surgeons and patients deciding the trade is worth it.
Why does China matter so much to STAAR?
+
China is STAAR's largest market by far: ~$52.3 million of the ~$93.5 million in second-quarter 2026 sales and ~$39.3 million of ~$83.4 million in the third quarter. High rates of myopia among young adults there make the ICL an attractive option, and public hospitals, especially mid-tier ones, drove the 2026 growth. The dependence cuts both ways. In 2025, distributors held too much inventory, shipments slowed sharply and full-year sales fell 23.7%. Management now describes the first and second quarters as China's peak season, with the third quarter stepping down. Tariffs on U.S.-made lenses sent to China also hurt margins until manufacturing for that market moved to Switzerland in the third quarter of 2026. Any change in Chinese demand, hospital purchasing policy or trade rules shows up in STAAR's numbers quickly.
Is STAAR Surgical profitable?
+
Yes, on a 2026 basis. The company earned ~$18.8 million of net income, or $0.37 per diluted share, in the first nine months of 2026, including ~$5.6 million ($0.11) in the third quarter and ~$8.1 million ($0.16) in the second. That followed a ~$80.4 million loss in 2025, much of it tied to the Chinese inventory reset, merger costs and a fourth-quarter loss of ~$18.3 million. Adjusted EBITDA reached ~$58.8 million over the nine months. Management expects strong full-year GAAP net income, positive free cash flow and a debt-free balance sheet for 2026, while warning that Chinese seasonality will hold back fourth-quarter revenue. Trailing twelve-month net income is close to zero because the weak fourth quarter of 2025 is still in the window.
Who runs STAAR Surgical now?
+
Warren Foust has been president and chief executive officer since August 4, 2026, and also sits on the board. He joined STAAR in April 2023 as chief operating officer, became president and COO in March 2025, and served as interim co-CEO with CFO Deborah Andrews from February 1, 2026 after former CEO Stephen Farrell left at the board's request following the failed Alcon vote. Andrews remains chief financial officer and became an executive vice president. The board was reshaped by the January 2026 cooperation agreement with Broadwood Partners: Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital joined, and board size is capped at seven until the 2027 annual meeting. In China, Ying Chen was elevated to president of STAAR Surgical China.
How is STAA valued compared with its history and the Alcon offer?
+
At ~$24.12 on November 20, 2026 and roughly 50.5 million shares, STAAR's market value is about ~$1.21 billion. Subtracting ~$206.4 million of cash and investments (there is no debt) leaves an enterprise value near ~$1.0 billion, or around 3.1 times trailing revenue of ~$328 million. In 2021, when Chinese growth looked unstoppable, the stock traded well above $100 and at far higher sales multiples, so the current price embeds much more caution. Relative to the takeover, the shares sit about 22% below Alcon's rejected $30.75 offer, and analysts' mean target of about $28.56 is closer to that level. Valuation in either direction mostly comes down to whether 2026's recovery in China holds and whether margins return toward the high 70s once tariff costs fade.
What are the main risks of owning STAAR Surgical stock?
+
The biggest risk is dependence on China, which supplied roughly half of sales in 2026 and caused a 23.7% drop in revenue in 2025 when distributor inventory had to be worked down. Domestic Chinese competition began in 2025 with Eyebright Medical's approved phakic lens, and hospital purchasing reforms could pressure prices. Tariffs cut gross margin to 70.9% in the third quarter of 2026, and U.S.-made product sold into China still faces them. STAAR sells essentially one product family, so any safety issue, recall or plant disruption would affect the whole company. Sales in Japan and South Korea declined in the third quarter, and U.S. sales remain small. Without the Alcon offer, nothing supports the price from below except the business itself, and the stock moved between ~$15.59 and ~$35.87 over the past year.
How has STAA stock performed in 2026?
+
As of November 20, 2026 STAA closed near $24.12, up about 2.2% year to date and 6.7% over the past month, but down about 11.8% over one year, a span that includes the failed Alcon vote in January. The 52-week range is about $15.59 to $35.87. Past performance does not predict future returns, and Walnut is not an investment adviser.
How did STAAR Surgical do in its latest quarter?
+
In the third quarter of 2026, reported November 4, STAAR posted sales of ~$83.4 million, down 12% from a year earlier because the prior-year quarter included ~$25.9 million of deferred China shipments, and net income of ~$5.6 million. Adjusted EPS of $0.19 was a cent below the $0.20 consensus, and gross margin fell to 70.9% on tariffs. Nine-month sales reached a record ~$270.5 million.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with STAAR Surgical Company's investor relations page or your broker before making investment decisions.